PMC7701665_01
Patients with refractory or relapsed mantle cell lymphoma achieved durable remission after CD19-4-1BB CAR-T cell treatment. (A) PET-CT scans at baseline and 3 months after CAR-T infusion in three patients who responded with complete remission. Examples of sites of lymphoma in this patient are indicated by the black arrows. (B) CD19-CAR+ cells in PBMCs were detected by quantitative PCR. Limit of detection of the qPCR assay is 0.001% or 1x10-5. (a) The first 6 months after CAR-T infusion, (b) Last time that CAR+ cells were detectable.
OTT-13-12163-g0001.jpg
PMC7701665_02_OTT-13-12163-g0001.jpg
f0001
The peak number of CAR-T cells appeared in 1-2 weeks after infusion and then decreased (Figure 1B(a)). CAR+ cells could be detected was 9 months and 15 months for Patient 2 and Patient 3, respectively (Figure 1B(b)). CD19-CAR-T cell therapy has been reported to cause persistent B-cell depletion and hypogammaglobulinemia in patients with leukemia and lymphoma.
PMC7701665_02
Patients with refractory or relapsed mantle cell lymphoma achieved durable remission after CD19-4-1BB CAR-T cell treatment. (A) PET-CT scans at baseline and 3 months after CAR-T infusion in three patients who responded with complete remission. Examples of sites of lymphoma in this patient are indicated by the black arrows. (B) CD19-CAR+ cells in PBMCs were detected by quantitative PCR. Limit of detection of the qPCR assay is 0.001% or 1x10-5. (a) The first 6 months after CAR-T infusion, (b) Last time that CAR+ cells were detectable.
OTT-13-12163-g0001.jpg
PMC7701665_02_OTT-13-12163-g0001.jpg
f0001
The peak number of CAR-T cells appeared in 1-2 weeks after infusion and then decreased (Figure 1B(a)). CAR+ cells could be detected was 9 months and 15 months for Patient 2 and Patient 3, respectively (Figure 1B(b)). CD19-CAR-T cell therapy has been reported to cause persistent B-cell depletion and hypogammaglobulinemia in patients with leukemia and lymphoma.
Assessment of serum immunoglobulins and B-cell recovery. (A) Immunoglobulins including IgG, IgA and IgM were monitored from all three patients before and after treatment with CD19-CAR-T cells. (B) Assessment of B cell recovery and phenotype of recovering B cells in Patient 3.
OTT-13-12163-g0002.jpg
PMC7701665_02_OTT-13-12163-g0002.jpg
f0002
We found a significant decrease of serum IgG and IgA levels after CAR-T therapy (Figure 2A). The recovering B cells were polyclonal, as evidenced by a normal ratio of kappa to lambda light chains on these B cells (Figure 2B).